Cup & Handle breakout, US listing & Potential short squeeze 🚀🚀
Looking at the daily candlestick chart over the past few months DDDD is definitely showing a cup and handle chart pattern although it’s not the best example of one. We are currently at a potential breakout of the handle and providing it surpasses the 139p ish mark we could see things takeoff for 4D. Below I’ve highlighted some catalysts that could be the reasons to support a breakout of the 139p mark.
Over the past month the handle has formed nicely, evident from lower highs and lower lows forming a descending parallel channel. This week that channel was broken setting us up nicely for a breakout of the handle.
4D based in Leeds UK are a company that focus on live biotherapeutic treatments. They have a variety of projects in their pipeline with many well into there phase two trial: MRx0518 - a trial looking at impacting a variety solid cancerous tumours & Blautix a treatment for irritable bowel syndrome. They also have a drug MRx-4DP0004 that is a treatment for Asthma but is currently being pushed to treat Covid patients which could see quicker than normal approval. They also have variety of other treatments they are perusing which can all be seen on their website.
4D are hugely undervalued in my opinion with a current market cap of 205mil their closest piers that you may argue are inferior to 4D have market caps that far surpass that of 4D: EEVOL $726 mil,
MCRB 2.2B.
4D will soon be trading on the US market with a Nasdaq listing LLBPS imminent with a date still yet to be announced but the company tweeted “we are still on track for Q1 2021” once the listing is live, with exposure on the US market I expect the share price to see some momentum as buyers take advantage of 4Ds current undervalued status. The company are seeking listing via a special acquisition company (LLOAC)
Citadel opened a short position up recently (which I personally think is bonkers) 4D has soo many more potential positives in the near future and for that reason I think the the chance of a short squeeze is more than likely adding even more momentum to justify a breakout.
Please note the above information should not be used to determine a position; do your own research before investing.
Over the past month the handle has formed nicely, evident from lower highs and lower lows forming a descending parallel channel. This week that channel was broken setting us up nicely for a breakout of the handle.
4D based in Leeds UK are a company that focus on live biotherapeutic treatments. They have a variety of projects in their pipeline with many well into there phase two trial: MRx0518 - a trial looking at impacting a variety solid cancerous tumours & Blautix a treatment for irritable bowel syndrome. They also have a drug MRx-4DP0004 that is a treatment for Asthma but is currently being pushed to treat Covid patients which could see quicker than normal approval. They also have variety of other treatments they are perusing which can all be seen on their website.
4D are hugely undervalued in my opinion with a current market cap of 205mil their closest piers that you may argue are inferior to 4D have market caps that far surpass that of 4D: EEVOL $726 mil,
MCRB 2.2B. 4D will soon be trading on the US market with a Nasdaq listing LLBPS imminent with a date still yet to be announced but the company tweeted “we are still on track for Q1 2021” once the listing is live, with exposure on the US market I expect the share price to see some momentum as buyers take advantage of 4Ds current undervalued status. The company are seeking listing via a special acquisition company (LLOAC)
Citadel opened a short position up recently (which I personally think is bonkers) 4D has soo many more potential positives in the near future and for that reason I think the the chance of a short squeeze is more than likely adding even more momentum to justify a breakout.
Please note the above information should not be used to determine a position; do your own research before investing.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.